{
    "nct_id": "NCT04623541",
    "official_title": "A Phase 1b/2, Open-Label, Safety and Efficacy Study of Epcoritamab (GEN3013; DuoBody®-CD3xCD20) in Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome",
    "inclusion_criteria": "Key Inclusion Criteria\n\n1. Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1 or 2.\n2. Evidence of CD20 positivity in a sample representative of the disease at Screening.\n3. Acceptable hematology parameters and organ function based on baseline bloodwork.\n4. Life expectancy >3 months on standard of care (SOC) for CLL, >3 months for RS.\n5. For R/R CLL arms - Must have active CLL/SLL disease requiring treatment per iwCLL 2018 criteria.\n6. For R/R CLL monotherapy arms - Received at least 2 prior lines of systemic anti-neoplastic therapy including a Bruton's tyrosine kinase (BTK) inhibitor or at least 1 prior line of systemic antineoplastic therapy, including treatment with (or intolerance of) a covalent BTK inhibitor (cBTKi) and a B-cell lymphoma 2 (BCL-2) inhibitor.\n7. For all RS arms - Have tumor biopsy-proven CD20+ Diffuse large B-cell Lymphoma (DLBCL) and a clinical history of CLL/SLL.\n8. For all RS arms - Must have measurable disease by fluorodeoxyglucose-positron emission tomography (FDG-PET) and computed tomography (CT) or magnetic resonance imaging (MRI) scan.\n9. For all RS arms - Must provide mandatory formalin-fixed, paraffin-embedded (FFPE) tumor biopsy sample.\n10. For RS - monotherapy arm: Deemed as ineligible for chemoimmunotherapy at investigator's discretion or participant who refuses to receive intensive chemotherapy\n11. For RS - lenalidomide combination therapy arm\n\n    * Deemed as ineligible for chemoimmunotherapy at the investigator's discretion, or participant who refuses to receive intensive chemotherapy.\n    * Eligible for treatment with lenalidomide.\n    * Must be willing to use contraception and adhere to the Lenalidomide Pregnancy Risk Minimization Plan\n    * A woman must agree not to breastfeed a child during treatment and for at least 28 days after discontinuation from study.\n12. For RS - R-CHOP combination Therapy Arm -\n\n    * Eligible for treatment with R-CHOP.\n    * Females of childbearing potential must use highly effective contraceptive measures while taking R-CHOP and for 12 months after stopping treatment.\n    * A woman must agree not to breastfeed a child during treatment or until 12 months after last treatment.\n13. For R/R CLL - venetoclax combination Therapy arm - after receiving at least 1 prior line of systemic antineoplastic therapy.\n\n    * Presence of measurable disease.\n    * Must take prophylaxis for tumor lysis syndrome (TLS).\n14. For R/R CLL pirtobrutinib combination Therapy arm:\n\n    * Must have active CLL/SLL disease requiring treatment per iwCLL 2018 criteria.\n    * Presence of measurable disease.\n    * Previous treatment with at least one and a maximum 3 prior lines of therapy including a cBTKi.\n    * Diagnosis of CLL/SLL that met published iwCLL criteria.\n15. Participants with TN HR CLL - Pirtobrutinib Combination Therapy Expansion:\n\n    * Diagnosis of CLL/SLL that met published iwCLL criteria 2018.\n    * Must have active CLL/SLL disease that needs treatment per iwCLL\n    * Must take prophylaxis for TLS based on their TLS risk evaluation upon initiation of trial drug.\n    * Must have one or more high-risk features.\n    * Presence of measurable disease.\n\nKey Exclusion Criteria\n\n1. Received prior treatment with a CD3×CD20 bispecific antibody.\n2. Received any prior allogeneic hematopoietic stem cell transplantation (HSCT) or solid organ transplantation.\n3. Received chimeric antigen receptor (CAR) T-cell therapy within 100 days or an investigational drug within 4 weeks, prior to first dose of trial drug.\n4. Autoimmune disease or other diseases that require permanent or high-dose immunosuppressive therapy.\n5. Received vaccination with live vaccines within 28 days.\n6. Clinically significant cardiac disease.\n7. Known current malignancy other than inclusion diagnosis.\n8. Has had major surgery within 4 weeks.\n9. Known history of human immunodeficiency virus (HIV).\n10. For R/R CLL arms - Any history of RS or evidence indicating a potential Richter's transformation.\n11. For R/R CLL - Venetoclax Combination Therapy arm: received venetoclax within 24 months prior to beginning venetoclax ramp-up for this trial or has progressed on venetoclax treatment.\n12. For all RS arms - Diagnosis of Richter's syndrome not of the DLBCL subtype such as Hodgkin's lymphoma, prolymphocytic leukemia.\n13. RS - Lenalidomide Combination Therapy and RS Monotherapy Arms - received more than 2 prior lines of therapy for RS.\n14. R/R CLL - Pirtobrutinib Combination Therapy Arm - Prior exposure to a non-covalent (reversible) BTK inhibitor or a BTK degrader.\n15. Pirtobrutinib Combination Therapy Expansion Arms:\n\n    * History of bleeding disorders or participants requiring therapeutic anticoagulation with warfarin or another vitamin K antagonist\n    * Require continuous treatment with or have received strong cytochrome P450 (CYP) 3A inhibitors or strong/moderate CYP3A inducers within 4 to 5 half-lives or 14 days prior to the first dose of pirtobrutinib.\n\nNOTE: Other protocol defined Inclusion/Exclusion criteria may apply.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "",
    "miscellaneous_criteria": ""
}